Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05387525 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial status: Recruiting to Active, Not RecruitingEnrollment target: estimated 450 to confirmed 447 · Study sites: 47 to 49 · Primary and study completion dates: Mar 2027 to Jul 2027v7Show 3 more changesShow less
Enrollment target: estimated 450 to confirmed 447
Study sites: 47 to 49
Primary and study completion dates: Mar 2027 to Jul 2027
MinorRe-verified, no change to tracked fieldsv6
MinorEnrollment target: 540 to 450v5
NotablePrimary and study completion dates: Mar 2026 to Mar 2027Study sites: 46 to 47v4Show 1 more changeShow less
Study sites: 46 to 47
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 41 to 46 · Start date changed from estimate of Aug 2022 to Oct 24, 2022v3Show 2 more changesShow less
Study sites: 41 to 46
Start date changed from estimate of Aug 2022 to Oct 24, 2022
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.